Recognizing the complexities of co‐prescriptions and life‐style factors in opioid agonist treatment: A response from Eleni Domzaridou, Matthew J. Carr, Tim Millar, Roger T. Webb and Darren M. Ashcroft-Reference-Cited by-同舟云学术

Recognizing the complexities of co‐prescriptions and life‐style factors in opioid agonist treatment: A response from Eleni Domzaridou, Matthew J. Carr, Tim Millar, Roger T. Webb and Darren M. Ashcroft

Published:2024-02-05 Issue:5 Volume:119 Page:967-968
ISSN:0965-2140
Container-title:Addiction
language:en
Short-container-title:Addiction

Author:

Domzaridou Eleni¹²^ORCID,Carr Matthew J.¹²,Millar Tim³,Webb Roger T.¹³,Ashcroft Darren M.¹²

Affiliation:

1. National Institute for Health and Care Research Greater Manchester Patient Safety Research Collaboration University of Manchester Manchester UK

2. Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK

3. Centre for Mental Health and Safety, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health University of Manchester Manchester UK

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.16447

Reference6 articles.

1. Comment on Domzaridou et al.: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment

2. Non‐fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records

3. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom

4. Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study

5. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database